Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that additional interim clinical data from an ongoing Phase IIa study of its novel anti-cancer drug candidate, Archexin® were recently presented at the 2016 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium. "We are excited about the results from our ongoing Phase IIa study of Archexin in renal cell carcinoma, which continue to look promising," said Dr. Ely Benaim, Chief Medical Officer for Rexahn. "Interim data presented in November 2015 showed that at the lowest dose of Archexin tested (125 mg/m2/day), one patient had stable disease for over a year and a 16% reduction in the size of the patient's primary tumor following four cycles of treatment. The latest data show a reduction in tumor size of 36% in a second patient receiving 200 mg/m2/day of Archexin following 2 treatment cycles, suggestive of a dose and time-dependent clinical benefit." Stage 2 of the clinical trial – a randomized, open-label, two-arm dose expansion study of Archexin in combination with everolimus, versus everolimus alone, is expected to start in early 2016 and will further evaluate the efficacy of Archexin in metastatic renal cell carcinoma (RCC). Rexahn has received U.S. Food and Drug (FDA) Orphan Drug Designation for Archexin for metastatic RCC as well as four other cancers.